A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma

Summary

The study will measure the change in lung function in subjects with asthma after inhaling from either of two inhalers: Albuterol Spiromax® or placebo.

Timeline

Start

2012-12

Primary completion

2013-10

Completion

2013-11

Outcome

Met primary endpoint

registry Placebo MDPI vs Albuterol MDPI; p <0.0001; Mean Difference (Final Values) 0.83 (95% CI 0.57 to 1.08) NCT01424813 ↗

Publications

• Raphael G, Taveras H, Iverson H, O'Brien C, Miller D. Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma. J Asthma. 2016;53(2):187-93. doi: 10.3109/02770903.2015.1070862. Epub 2015 Sep 15.

Drugs

Indications